Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrico Breda

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Gynecologic Oncology|May 18, 2016
Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancerAmreen Husain, Yan Wang, Lars C Hanker, et al.
Gynecologic Oncology|March 27, 2012
Ovarian Sertoli-Leydig cell tumors. a retrospective MITO studyCristina Sigismondi, Angiolo Gadducci, Domenica Lorusso, et al.
Gynecologic Oncology|December 21, 2014
Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary?Jessica Ottolina, Gabriella Ferrandina, Angiolo Gadducci, et al.
Critical Reviews in Oncology/Hematology|February 5, 2008
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) studySandro Pignata, Enrico Breda, Giovanni Scambia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancerGabriella Ferrandina, Manuela Ludovisi, Domenica Lorusso, et al.
Gynecologic Oncology|June 25, 2005
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survivalGabriella Ferrandina, Ida Paris, Manuela Ludovisi, et al.
Journal of Pain and Symptom Management|May 8, 2010
Breakthrough pain in oncology: a longitudinal studySebastiano Mercadante, Vittoria Zagonel, Enrico Breda, et al.
Cancer Chemotherapy and Pharmacology|March 7, 2009
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trialCarmela Pisano, Alessandro Morabito, Roberto Sorio, et al.
Gynecologic Oncology|March 30, 2021
Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study databaseFrancesca Falcone, Enrico Breda, Gabriella Ferrandina, et al.
BMC Cancer|August 3, 2006
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trialSandro Pignata, Giovanni Scambia, Antonella Savarese, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Gynecologic Oncology|May 18, 2016
Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancerAmreen Husain, Yan Wang, Lars C Hanker, et al.
Gynecologic Oncology|March 27, 2012
Ovarian Sertoli-Leydig cell tumors. a retrospective MITO studyCristina Sigismondi, Angiolo Gadducci, Domenica Lorusso, et al.
Gynecologic Oncology|December 21, 2014
Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary?Jessica Ottolina, Gabriella Ferrandina, Angiolo Gadducci, et al.
Critical Reviews in Oncology/Hematology|February 5, 2008
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) studySandro Pignata, Enrico Breda, Giovanni Scambia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancerGabriella Ferrandina, Manuela Ludovisi, Domenica Lorusso, et al.
Gynecologic Oncology|June 25, 2005
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survivalGabriella Ferrandina, Ida Paris, Manuela Ludovisi, et al.
Journal of Pain and Symptom Management|May 8, 2010
Breakthrough pain in oncology: a longitudinal studySebastiano Mercadante, Vittoria Zagonel, Enrico Breda, et al.
Cancer Chemotherapy and Pharmacology|March 7, 2009
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trialCarmela Pisano, Alessandro Morabito, Roberto Sorio, et al.
Gynecologic Oncology|March 30, 2021
Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study databaseFrancesca Falcone, Enrico Breda, Gabriella Ferrandina, et al.
BMC Cancer|August 3, 2006
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trialSandro Pignata, Giovanni Scambia, Antonella Savarese, et al.
Pageof 3